31
Oct
2023
Nimbus HPK1 Inhibitor Activates Immune System Against Tumors in Early Clinical Trial
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
28
Oct
2023
How The Unmet Needs of Patients Made Me A (Grounded) BioTechno-Optimist
My Ground Truth Every other week, I stroll across the Longfellow Bridge from Cambridge to Boston. It can be a magnificent walk in the fall and spring, when the weather is temperate and the skies clear. You can see the deep blue of the Charles River, the Esplanade on your left, with the Boston skyline behind it, and the Citgo... Read More
26
Oct
2023
Merck’s ADC Wager, Roche Enters TL1A Rivalry, & OrbiMed Signals Time to Buy
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Oct
2023
Aiolos Bio, With $245M from Atlas, Bain, Aims at TSLP for Asthma
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
19
Oct
2023
Thermo’s $3.1B Proteomics Bet, UCB’s Rare Two-Fer, & More Cutbacks
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
16
Oct
2023
Catching Cancer Early, Investing in Data and AI: Jeff Huber on The Long Run
Today’s guest on The Long Run is Jeff Huber. He’s the co-founder and general partner at Triatomic Capital. It’s a relatively new venture fund that seeks to back “century-defining” businesses in Engineered Biology, New Materials, Next Gen Compute, New Energy, & Automated Economy. Jeff and his fellow partners are looking at startups that collect and analyze data to address big... Read More
12
Oct
2023
Another GLP-1 Victory, Bayer Invests in Berkeley, & EU Tells Illumina to Divest
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
Oct
2023
An mRNA Nobel, Lilly Acquires Point, and Investment in Singapore
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
Oct
2023
Fulfilling the Promise of Sickle Cell Gene Therapy
Two gene therapies for sickle cell disease, CRISPR/Vertex’s exa-cel and Bluebird Bio’s lovo-cel, are being reviewed by the FDA and are likely to win US approval for sale by the end of the year. While it will take more time to fully establish long-term safety and efficacy of these therapies, they offer a glimmer of hope for a cure. This... Read More
3
Oct
2023
Targeted Radiation for Cancer: Lori Lyons-Williams on The Long Run
Today’s guest on The Long Run is Lori Lyons-Williams. She’s the CEO of Menlo Park, Calif. and Vancouver, BC-based Abdera Therapeutics. Abdera is a startup developing targeted antibody drugs loaded with potent microdoses of radiation to give them extra tumor-killing punch. This type of treatment modality has been around for decades. Targeted radiation hasn’t lived up to the full potential... Read More
19
Sep
2023
Turning the Tables: Rob Perez Interviews Me on The Long Run
This episode is unusual. Many listeners know of Rob Perez. He’s an operating partner at General Atlantic, the former CEO of Cubist Pharmaceuticals, and the founder of Life Science Cares. Rob and I have gotten to know each other better the past couple years through our shared passion for mobilizing the biotech community to fight poverty. The Timmerman Traverse for... Read More
11
Sep
2023
Sterile Information: Early Forecasting Not The Answer To R&D Productivity Woes
Two recent Wall Street Journal deep-dives nicely bookend a critical, and unresolved, tension faced by large pharmaceutical companies: how can their R&D organizations discover, develop, and deliver the new medicines patients await, and the growth and return on investment that shareholders demand? Early this year, I discussed an April 2023 profile of Lilly by journalist Peter Loftus, who described how the company, led by a physician-scientist... Read More
6
Sep
2023
Freeing the Biotech Founders: Zach Weinberg and Alexis Borisy on The Long Run
Today there are two guests on The Long Run: Zach Weinberg and Alexis Borisy. They are co-founders of Curie.Bio. Curie is a venture capital fund with $520 million, mostly for seed investments and Series A rounds in biotech startups. It also is also building up in-house R&D expertise which it uses to help the entrepreneurs it backs. Curie pitches itself... Read More
5
Sep
2023
A Return to Kilimanjaro: Timmerman Traverse for Damon Runyon Cancer Research
Welcome to the next big biotech expedition — Timmerman Traverse for Damon Runyon Cancer Research Foundation. A team of executives, investors, and scientists are coming together on Kilimanjaro, the highest peak in Africa, in February 2024. We’re on a mission to raise $1 million for young scientists across the US. Damon Runyon gives promising young researchers the freedom to pursue... Read More
31
Aug
2023
Danaher Wins Over Abcam, Sage Cuts, & FTC Ceases Fire With Amgen
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Aug
2023
Rapport’s $150M Advance, Regeneron’s New COVID Challenge, and a Traverse for the Ages
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Aug
2023
How ‘Living Medicine’ Came to Be: Fred Appelbaum on The Long Run
Today’s guest is Fred Appelbaum. Fred is a physician, scientist, and administrator. He’s an executive vice president at the Fred Hutchinson Cancer Center in Seattle. He’s also the author of a new book, “Living Medicine: Don Thomas, Marrow Transplantation and the Cell Therapy Revolution” published by Mayo Clinic Press. It’s excellent. Fred knows a lot of this story from firsthand... Read More
17
Aug
2023
Gilead Bets on Multi-Functionals, Taysha Revived & Google Spotlights Illumina Rival
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
10
Aug
2023
Sage Gets FDA OK for PPD, Wegovy’s Home Run, & Illumina’s Gloomy Quarter
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
10
Aug
2023
Challenges of Adopting Data Science & AI in Pharma/Biotech
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.